Podcasts about favipiravir

Pharma industry's Robinhood, Cipla is looking to increase its presence in the US market, the company's MD and Global CEO Umang Vohra. In this edition of The Medicine Box Podcast, CNBC-TV18's Ekta Batra talks to Vohra about Cipla's plan to capture a larger share of the US market, the firm's COVID-19 portfolio – from Tocilizumab to Remdesivir to Favipiravir, new products, growth outlook and more. Cipla, which is India's third largest pharma company and is present in more than 80 countries with over 46 manufacturing facilities, is looking to manufacture complex drugs and injectables in respiratory and cancer segments, Vohra said. Tune in to The Medicine Box Podcast for more 

Edzard Ernst joins us to tell all about his new book. Before we get into the interview with Edzard Ernst we are a bit nostalgic about hearing that the end of the ISS is getting closer. András has an update to the Favipiravir controverse from last week and then we get to hear from the horses mouth how Prince Charles became the ‘Alternative Prince'. IN TWISH we learn about Dmitri Mendeleev and his periodic table. After that, we get into the news: SWEDEN: Agency to tackle foreign misinformation re-established ROMANIA: 2/3 people believe COVID was imposed on the world by global elite for control, 1/3 thinks microchips are being implanted with vaccination SWITZERLAND: Man in Geneva hears God after antibiotic treatment INTERNATIONAL: Cranky Uncle game now available in Dutch and German Enjoy! Segments: Intro; Greetings; Interview; TWISH; News; Quote And Farewell; Outro; Out-Takes;

A Szkeptikus Hétfő keretében Para-Kovács Imre Pintér Andrással beszélgetett arról, hogy miért nem szerencsés feljelenteni azokat, akik nem értenek egyet az OGYÉI-vel

A Szkeptikus Hétfő keretében Para-Kovács Imre Pintér Andrással beszélgetett arról, hogy miért nem szerencsés feljelenteni azokat, akik nem értenek egyet az OGYÉI-vel

A Klubrádió Reggeli Gyors című műsorának vendégeként Pintér András beszélt az OGYÉI vitatható lépéséről a Favipiravir kapcsán

A Klubrádió Reggeli Gyors című műsorának vendégeként Pintér András beszélt az OGYÉI vitatható lépéséről a Favipiravir kapcsán

La Organización Panamericana de la Salud (OPS), 11 de enero de 2022. Publica, la 31ª edición de la base de datos de evidencia sobre posibles opciones terapéuticas para COVID-19. Examina 171 opciones terapéuticas. Según el portal de búsqueda de la Plataforma Internacional de Registro de Ensayos Clínicos (ICTRP) de la OMS, se están investigando cientos de posibles tratamientos o sus combinaciones en más de 10.000 ensayos clínicos y estudios observacionales. Treinta hallazgos clave. 1• Corticosteroides: 2• Remdesivir: 3• Hidroxicloroquina, interferón beta 1-a y lopinavir-ritonavir: 4• Antibióticos: 5• Plasma de convalecientes 6• Tocilizumab: 7• Sarilumab: 8• Anakinra: 9• Tofacitinib: 10• Colchicina: 11• Ivermectina: 12• Favipiravir: 13• Sofosbuvir con o sin daclatasvir, ledipasvir, velpatasvir o ravidasvir: 14• Baricitinib: 15• Casirivimab e Imdevimab (REGEN-COV 16• Bamlinivimab con o sin etesevimab 17• Sotrovimab: 18• Regdanvimab 19• Proxalutamide: 20• Dapagliflozina 21• Trasplante de células madre mesenquimatosas 22• Corticosteroides inhalados 23• Fluvoxamina: 24• Lenzilumab: 25• Fragmentos policlonales de anticuerpos equinos (INM005): 26• Famotidina: 27• Anticoagulantes: 28• Antiinflamatorios no esteroideos (AINE): 29• IECA y ARB 30• Molnupiravir: Conclusiones. 1• La Organización Panamericana de la Salud (OPS) hace seguimiento en todo momento de la evidencia en relación con cualquier posible intervención terapéutica. A medida que se disponga de evidencia nueva, la OPS la incorporará con rapidez y actualizará sus recomendaciones, especialmente si dicha evidencia se refiere a grupos en situación de vulnerabilidad como los niños y niñas, las mujeres embarazadas, las personas mayores o los pacientes inmunocomprometidos, entre otros. 2• La OPS también tiene en cuenta las diferencias en el impacto de la COVID-19 sobre las minorías y los diferentes grupos étnicos. En consecuencia, la Organización recopila constantemente información que pueda servir para mitigar el exceso de riesgo de enfermedad grave o muerte de estas minorías. Estos grupos sufren inequidades sociales y estructurales que conllevan una carga de enfermedad desproporcionada. 3• La seguridad de los pacientes afectados por la COVID-19 es una prioridad clave de la mejora de la calidad de la atención y los servicios de salud. 4• Sigue siendo apremiante la necesidad de elaborar ensayos clínicos aleatorizados de alta calidad que incluyan pacientes con COVID-19 a fin de poder desarrollar estrategias de manejo confiables. La importancia de los ensayos clínicos controlados aleatorizados con un diseño adecuado es fundamental en la toma de decisiones basadas en la evidencia. Hasta el momento, la mayoría de la investigación en el campo de la COVID-19 tiene muy baja calidad metodológica, lo que dificulta su identificación y validación. Urge incrementar la transparencia y plantear estudios de más calidad. REFERENCIA. https://iris.paho.org/handle/10665.2/52719 ADAPTACION PARA AUDIO-OYENTES: Medicina en una página. Dirección y Conducción: John Jarbis García Tamayo.

Az Első kézből első idei epizódjában Magyarország és Amerika Covid-gyógyszereiről, majd a németországi kannabisz-liberalizációról, a CBD-olajról és az orvosi marihuánáról beszélgetünk.

Hallgassa meg a legfrissebb híreket, tényleg csak pár perc! A közélet, gazdaság aktuális híreiről, a társadalmat érintő változásokról röviden szól a friss hírek podcastunk. A felolvasott hírek itt érhetőek el: https://podcast.hirstart.hu/friss-hirek/2022/01/07/6169/

Koronapandemien vil ingen ende ta, smittetallene øker, innleggelser øker, nye tiltak vurderes både i Norge og ellers i Europa – men hva hvis det finnes et medikament som kan forhindre alvorlig sykdom og død? Document møter lege Peter Dvergsdal som behandler koronapasienter med Favipiravir. Dvergsdal har importert medikamentet fra Japan siden høsten 2016, men i januar 2020 sa det stopp. Da ville ikke Statens Legemiddelverk godkjenne søknadene for import av medikamentet lenger, enda det har vært brukt mot koronavirus tidligere. Hvorfor setter ikke helsemyndighetene alle kluter til, når det finnes medisiner som kan redde liv, og isteden satser alt på vaksinasjon og nedstengning? Hvordan virker antivirale midler? Velkommen til intervju med Peter Dvergsdal.   Lag en konto på Odysee her! – Odysee vil da gi oss poeng som hjelper oss å klatre i algoritmene! Følg oss på Rumble. Følg oss også på PodBean, iTunes og alle steder der podcasts finnes. Husk å rate oss med 5 stjerner, så flere likesinnede sannhetssøkere finner oss der! Kjøp Alf R. Jacobsens politiske bombe «Stalins svøpe: KGB, AP og kommunismens medløpere» her!

CHP Ankara Milletvekili Murat Emir, koronavirüs tedavisinde tarihi geçmiş Favipiravir ilaçlarının kullanıldığını açıkladı. Emir, Sağlık Bakanlığı'na ilişkin Sayıştay raporlarının taslağına da ulaşarak kamuoyuyla paylaşılmayan usulsüzlükleri anlattı. Bugünkü Sağlık Bakanlığı bütçesi görüşmelerine dair de konuşan Murat Emir, Sağlık Bakanlığı'nın bütçe ile ilgili kararlarına ilişkin, “Bütçenin ana tercihinin yurtiçindeki beşli çeteyi ve yurtdışındaki ortakları zengin etmeye yönelik olduğunu görüyoruz. Kamu-özel ortaklığı adı altında yapılan şehir hastaneleriyle özel sermaye yabancılara ve Türkiye'deki belirli müteahhit gruplarına anormal kaynak aktarımı söz konusu. Kamunun 1 liraya yapacağı hastane için özel şirkete 7-8 lira ödendiğini görüyoruz, büyük bir soygun düzeni söz konusu” diye konuştu.

Find out how Thailand is seeking to solve Favipiravir shortages and hear the latest on Covid-19 drugs being used in Thailand! See omnystudio.com/listener for privacy information.

Find out how Thailand is seeking to solve Favipiravir shortages and hear the latest on Covid-19 drugs being used in Thailand! See omnystudio.com/listener for privacy information.

Türkiye'de coronavirüs tedavisinde kaç ilaç kullanılıyor? Hangi aşamalarda hangisi kullanılıyor? -Favipiravir tartışılan ilaç. Neden tartışılıyor? Covid olan kullanmamalı? Neden? -Bugün Türkiye'de Covid olan biri hangi ilaçları kullanmalı, hangilerini tavsiye edersiniz? -Dünyada hangi ilaçlar kullanılıyor? Hangileri tedavide etkili ilaçlar? -Tedavi haricinde Covid hastalarına önerdiğiniz alternatif yöntemler var mı? Deniz Kilislioğlu soruyor, Ankara Üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları Ana Bilim Dalı Başkanı Prof.Dr. İsmail Balık yanıtlıyor.

BPOM merilis izin edar obat-obatan untuk penyembuhan Covid-19. Dari 12 obat yang mengadung zat Remdesivir dan Favipiravir, Ivermectin nggak masuk di dalam daftar tersebut.

With the kind permission of investigative author John Leake—who recently joined us on the programme—TMR presents his important interview with the brilliant and courageous Dr Peter A McCullough. In the words of John Leake: "Dr. Peter McCullough has been the world's most prominent and vocal advocate for early outpatient treatment of SARS-CoV-2 (COVID-19) infection in order to prevent hospitalization and death. On May 19, 2021, I interviewed him about his efforts as a treating physician and researcher. From his unique vantage point, he has observed and documented a profoundly disturbing policy response to the pandemic—a policy response that may prove to be the greatest malpractice and malfeasance in the history of medicine and public health." "Dr McCullough is an internist, cardiologist, epidemiologist, and Professor of Medicine at Texas A & M College of Medicine, Dallas, TX USA. Since the outset of the pandemic, Dr McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 40 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill and on FOX NEWS Channel. On November 19, 2020, Dr McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs and throughout 2021 in the Texas Senate Committee on Health and Human Services, Colorado General Assembly, and New Hampshire Senate concerning many aspects of the pandemic response." [The audio included in this podcast is Copyright © 2021 John Leake, all rights reserved, and used here with express permission.] For show notes please visit https://themindrenewed.com

With the kind permission of investigative author John Leake—who recently joined us on the programme—TMR presents his important interview with the brilliant and courageous Dr Peter A McCullough. In the words of John Leake: "Dr. Peter McCullough has been the world's most prominent and vocal advocate for early outpatient treatment of SARS-CoV-2 (COVID-19) infection in order to prevent hospitalization and death. On May 19, 2021, I interviewed him about his efforts as a treating physician and researcher. From his unique vantage point, he has observed and documented a profoundly disturbing policy response to the pandemic—a policy response that may prove to be the greatest malpractice and malfeasance in the history of medicine and public health." "Dr McCullough is an internist, cardiologist, epidemiologist, and Professor of Medicine at Texas A & M College of Medicine, Dallas, TX USA. Since the outset of the pandemic, Dr McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 40 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill and on FOX NEWS Channel. On November 19, 2020, Dr McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs and throughout 2021 in the Texas Senate Committee on Health and Human Services, Colorado General Assembly, and New Hampshire Senate concerning many aspects of the pandemic response." [The audio included in this podcast is Copyright © 2021 John Leake, all rights reserved, and used here with express permission.] For show notes please visit https://themindrenewed.com

We are amidst a pandemic, a public health emergency. And there is a clutter of information available out there on the internet, on social media, on 'Whatsapp University'. In order to declutter all of that and bring forth important handy guidelines to refer to in these times, we invited Dr. Pankaj Narvekar to talk about the situation and share some important information. Dr. Narvekar has been working with the Covid facility at NSCI Dome, Worli for more than a year. He tells us about:-His life as a Covid Warrior-Identifying the symptoms of the disease-How to manage home isolation and when to consider hospitalization-About Oxygen requirements-About the medicines used to manage the virus-About the Vaccines-Safety ProtocolsTune In, and do share it with everyone. Let's keep misinformation at bay.

Un artículo publicado hace unas horas en una revista científica de prestigio revela las causas del fallo de dos medicamentos prometedores en la lucha contra COVID-19, el lopinavir y la hidroxicloroquina. Estos resultados sirven para contemplar con precaución la promesa de otros medicamentos que han sido mencionados frecuentemente en las últimas semanas. Gracias por sus comentarios y apoyo, recuerde que puede apoyarnos donando en PayPal https://www.paypal.com con el correo elexplicadorpatrocinio@gmail.com y en Patreon en El Explicador Enrique Ganem https://www.patreon.com/user?u=18159632. Lo invitamos a suscribirse a este canal para recibir avisos de nuevas publicaciones y a visitar nuestra página http://www.elexplicador.net. En el titulo de nuestros trabajos aparece en primer lugar la fecha año/mes/día de publicación, lo que facilita su consulta cronológica. Siempre leemos sus comentarios, muchas veces no tenemos tiempo para reponder a cada uno personalmente pero son leídos y tomados en cuenta, los iremos respondiendo según nos sea posible. Este es un espacio de divulgación científica en el que nos interesa informar de forma clara y amena, que le invite a Ud. a investigar sobre los temas tratados y Ud. forme su propia opinión. Serán borrados los comentarios que promuevan la desinformación, charlatanería, odio, bullying, violencia verbal o incluyan enlaces a páginas que no sean de revistas científicas arbitradas, sean ofensivos hacia cualquier persona o promuevan alguna tendencia política ya sea en el comentario o en la fotografía de perfil. Aclaramos que no somos apolíticos, nos reservamos el derecho de no expresar nuestra opinión política, este es un canal cuya finalidad es la divulgación científica. Gracias por su preferencia. AVISO: En la área inferior de nuestros vídeos aparece un recuadro de la Secretaría de Salud con una liga, queremos aclarar que estos letreros aparecen sin nuestro conocimiento o notificación previa alguna y que no nos están patrocinando en forma alguna. ACLARACIÓN IMPORTANTE: El virus SARS- CoV-2 y la enfermedad COVID-19 SI EXISTEN, SON REALES. Le sugerimos que siga atentamente las recomendaciones de la Secretaría de Salud: higiene, mascarilla o tapaboca cuando salga de su domicilio y sobre todo quédese en casa cuando no sea indispensable salir.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.06.240325v1?rss=1 Authors: Seifert, M., Bera, S. C., van Nies, P., Kirchdoerfer, R. N., Shannon, A., Le, T.-T.-N., Grove, T. L., Papini, F. S., Arnold, J. J., Almo, S. C., Canard, B., Depken, M., Cameron, C. E., Dulin, D. Abstract: Coronavirus Disease 2019 (COVID-19) results from an infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the third coronavirus outbreak to plague humanity this century. Currently, the most efficacious therapeutic against SARS-CoV-2 infection is the Remdesivir (RDV), an adenine-like ribonucleotide analogue that is very efficiently incorporated by the SARS-CoV-2 replicase. Understanding why RDV is so well incorporated will facilitate development of even more effective therapeutics. Here, we have applied a high-throughput, single-molecule, magnetic-tweezers platform to study thousands of cycles of nucleotide addition by the SARS-CoV-2 replicase in the absence and presence of RDV, a Favipiravir-related analog (T-1106), and the endogenously produced ddhCTP. Our data are consistent with two parallel catalytic pathways of the replicase: a high-fidelity catalytic (HFC) state and a low-fidelity catalytic (LFC) state, the latter allowing the slow incorporation of both cognate and non-cognate nucleotides. ddhCTP accesses HFC, T-1106 accesses LFC as a non-cognate nucleotide, while RDV efficiently accesses both LFC pathway. In contrast to previous reports, we provide unequivocal evidence against RDV functioning as a chain terminator. We show that RDV incorporation transiently stalls the replicase, only appearing as termination events when traditional, gel-based assays are used. The efficiency of ddhCTP utilization by the SARS-CoV-2 replicase suggests suppression of its synthesis during infection, inspiring new therapeutic strategies. Use of this experimental paradigm will be essential to the development of therapeutic nucleotide analogs targeting polymerases. Copy rights belong to original authors. Visit the link for more info

The COVID-19 pandemic has gotten the global scientific community to swing into action to find an urgent cure.With the infection numbers reaching 8 million worldwide, several researches, studies and trials are being carried out simultaneously to urgently look into the effects of anti-viral drugs, steroids and repurposed drugs on COVID-19 patients.In just over the last month, there have been a few developments.An old, cheap, anti-inflammatory drug dexamethasone has recently been touted as a treatment for COVID-19 to reduce mortality. Even the WHO, on 23 June, has asked to ramp up the production of this widely used steroid, after clinical trials found it to have life-saving potential for critically-ill coronavirus patients in the UK.Another drug, Remdesivir, initially developed by Gilead Sciences to work against Ebola, has demonstrated faster recovery among COVID-19 patients. It has now been launched into production by the drugmaker Cipla under its brand name Cipremi.And Glenmark Pharmaceuticals has also launched anti-viral drug Favipiravir for the treatment of mild-to-moderate COVID-19 cases after receiving ‘restricted emergency' approval from the Drug Controller General of India to manufacture and market the medicine.But how optimistic are doctors and experts about these developments? Tune in to The Big Story!Producer and Host: Shorbori PurkayasthaGuest: Dr Sumit Ray, Critical Care Specialist in Delhi-NRCEditor: Shelly WaliaMusic: Big Bang FuzzListen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng

Chairing an all-party meeting on the violent clash in Galwan in which 20 Indian soldiers lost their lives, Prime Minister Narendra Modi on Friday said, “Neither has anybody intruded into our territory, nor is anybody inside our territory, nor any of our posts have been captured,” drawing strong reactions on social media. Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The BCCI on Friday said it will review IPL's sponsorship deals, including the one with Chinese mobile manufacturing company Vivo, in a meeting next week after 20 Indian soldiers were killed during a clash with Chinese troops in eastern Ladakh. Download the Deccan Herald app for Android devices here: https://bit.ly/2UgttIO Download the Deccan Herald app for iOS devices here: https://apple.co/30eOFD6 For latest news and updates, log on to www.deccanherald.com Check out our e-paper www.deccanheraldepaper.com To read news on the go, sign up to our Telegram channel t.me/deccanheraldnews

Dr. Teo presents a thorough review of the currently available treatment options for COVID-19 disease. He begins by summarizing the evidence for available antiviral treatment options. Next, he discusses the available data for several pharmacologic support therapies currently under investigation. Lastly, he presents the NIH and/or IDSA recommendations regarding those therapies. Therapies discussed include hydroxychloroquine, remdesivir, HIV protease inhibitor, Favipiravir, Tocilizumab, interferons, and others. Dr. Teo also looks at convalescent plasma and its promising role in certain patients with severe COVID-19.

Welcome to the emDOCs.net podcast with Brit Long, MD (@long_brit) and Manpreet Singh, MD (@MprizzleER)! Join us as we review our high-yield posts from our website emDOCs.net. This episode covers therapies in COVID, first looking at antivirals, and second, at hydroxychloroquine (HC) and chloroquine (CQ). The original antiviral post was released on March 30 and the HC and CQ post on April 6. Needless to say, there have been several significant updates in the literature concerning these agents. Today, we are going to focus on these and provide some more insights. The details of all studies discussed in the podcast are below in the post. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

Covid-19: Pune-based drug firm to export favipiravir to 18 countries

Hikal freezes at 5% upper circuit on development of Favipiravir API

İlginç Zamanların Gündemi (18-24 Mart) | #76 (24 Mart 2020) Bilal Eren ve Cem Sünbül ile teknoloji çağının haftalık gündemini her salı saat 22.00'da DijitalHayatTV YouTube/Facebook/Periscope/LinkendIn canlı yayınında değerlendiriyoruz; - Huawei, Ambargoyu Delmeye Çalışıyor! - Bill Gates, Microsoft'tan İstifa Etti! - Tokyo Olimpiyatları Ertelendi! - Küresel Salgın'ın Avantajları Olur mu? - Siber Güvenlik Dergisi Arka Kapı Ücretsiz - Google Meet Ücretsiz! - Micrsosoft Teams Ücretsiz! - Karantina ve İnternet Günleri - WhatsApp Server Yatırımı Yaptı! - Netflix ve YouTube Görüntü Kalitesini Düşürdü! - PUBG, 600 Milyon Kez İndirildi. - Netflix Aboneliği Veren Belediye! - Kişisel Güvenlik mi, Koronavirüs mü: İsrail ve Avusturya Hastaları Telefonlarından Takip Edecek! - Koronavirüs Aşı ve İlaç Çalışmaları Ne Durumda? - Favipiravir İlacı Hastalığı Hafifletiyor mu? - Yerli Koronavirüs Tanı Kiti Var mı? - Migros Sanal Market 1000 Kişiyi İşe Alacak! Haftaya salı saat 22.00'da canlı yayında görüşmek üzere. Hem canlı hem de geçmiş yayınlarımız için tıklayın; YouTube: https://www.youtube.com/dijitalhayattv Facebook: https://www.facebook.com/dijitalhayattv Twitter: https://www.twitter.com/dijitalhayattv Web: https://www.dijitalhayat.tv